Last reviewed · How we verify
MBI 226
MBI 226 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or inflammatory pathway to enhance anti-tumor immunity or reduce pathological inflammation.
MBI 226 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or inflammatory pathway to enhance anti-tumor immunity or reduce pathological inflammation. Used for Cancer (specific indication not publicly detailed).
At a glance
| Generic name | MBI 226 |
|---|---|
| Sponsor | BioWest Therapeutics Inc |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
While the exact molecular target of MBI 226 has not been widely disclosed in public literature, it is being developed by BioWest Therapeutics as an immunotherapeutic agent in Phase 3 clinical trials. The drug is designed to modulate immune responses, likely through blockade of an inhibitory receptor or enhancement of effector cell function, to treat cancer or inflammatory conditions.
Approved indications
- Cancer (specific indication not publicly detailed)
Common side effects
Key clinical trials
- Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne (PHASE2)
- Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne (PHASE2)
- Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MBI 226 CI brief — competitive landscape report
- MBI 226 updates RSS · CI watch RSS
- BioWest Therapeutics Inc portfolio CI